It's more important than ever before for your elected officials to hear from you - don't miss your chance to turn Capitol ...

Phase 3 trial data show subcutaneous anifrolumab improves BICLA response rates and reduces oral corticosteroid use in ...

Johnson & Johnson announced positive topline results from its Phase 2 randomized placebo-controlled JASMINE study. The drug ...

Lupus affects women at disproportionately high rates— roughly 9 out of 10 patients are female —and research consistently ...

As with the intravenous form, subcutaneous anifrolumab shows clinically meaningful benefits and favorable safety when added ...

Fresh off of a European approval for a subcutaneous version of Saphnelo, AstraZeneca is doubling down on the benefits of the ...

The optimal hydroxychloroquine blood level in lupus is between 750 ng/mL and 1,150 ng/mL, which can help prevent active ...

Lupus is often marked by flares, which is when symptoms are usually more obvious.

Investigators compared the risk of cancer onset in patients with lupus nephritis treatedwith calcineurin inhibitors vs ...

We’re all mostly human. 8% of your genome comes from viruses. In A Nutshell Scientists captured the first detailed images of ...

The total market size of systemic lupus erythematosus is expected to increase in the 7MM during the forecast period, driven by ongoing clinical research of therapies such as nipocalimab (Johnson & ...